Skip to Content
Merck
All Photos(1)

Documents

R1158

Sigma-Aldrich

Ribonuclease Inhibitor

recombinant, expressed in E. coli, 20-40 units/μL

Synonym(s):

RNAse inhibitor

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

MDL number:
MFCD00132187
UNSPSC Code:
12352200
NACRES:
NA.52

recombinant

expressed in E. coli

Quality Level

300

grade

for molecular biology

form

buffered aqueous solution

mol wt

~50 kDa

concentration

20-40 units/μL

shipped in

dry ice

storage temp.

−20°C

Looking for similar products? Visit Product Comparison Guide

General description

Ribonuclease inhibitor works to inhibit RNase activity by forming a tight, non-covalent 1:1 complex. It is derived from E. coli which expresses portions of the human placental ribonuclease inhibitor. It inhibits RNases A, B, and C. It will not inhibit RNases H, 1, T1, S1 Nuclease, SP6, T7 RNA Polymerase, T3 RNA Polymerase, AMV Reverse Transcriptase, M-MLV Reverse Transcriptase, or Taq Polymerase. The inhibitor can be removed by phenol extraction or by heating to 65°C for 10 minutes. The pH range for inhibition is pH 5.5–9 (highestinhibition at pH 7–8).

Application

Ribonuclease Inhibitor is suitable for use in useful for in vitro inhibition of ribonucleases, including procedures like:

  • cDNA synthesis from mRNA
  • reverse transcriptase polymerase chain reaction (RT-PCR)
  • in vitro transcription and translation
  • mRNA protection from degradation
  • formaldehyde cross-linked lncRNA purification
  • RNA-fluorescence in situ hybridization (FISH)
Useful for in vitro inhibition of ribonucleases, including procedures like cDNA synthesis, RT-PCR, and in vitro transcription and translation.

Biochem/physiol Actions

Inhibits RNase by forming a tight, non-covalent 1:1 complex.

Components

Ribonuclease Inhibitor is provided as a solution in 20 mM HEPES-KOH( pH 7.6), 50 mM KCl, 8 mM DTT and 50% glycerol.

Unit Definition

One unit will reduce the activity of 5 ng of ribonuclease A by 50% in a cytidine 2′:3′-cyclic monophosphate system.

Physical form

Solution in 20 mM HEPES-KOH, pH 7.6, 50 mM KCl, 8 mM DTT and 50% glycerol.

Other Notes

  • Denaturing conditions (i.e., urea or temperatures ≥50 °C) should be avoided as they may cause a release of active ribonuclease from the complex.
  • This product is for R&D use only, not for drug, household, or other uses.

related product

Product No.
Description
Pricing

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lintao Li et al.
Cell cycle (Georgetown, Tex.), 22(4), 476-493 (2022-11-13)
Whether long non-coding RNA Mir-99a-Let-7c Cluster Host Gene (LncRNA MIR99AHG) is involved in osteoporosis (OP) remains vague, so we hereby center on its implication. Old C57BL/6J mice were injected with the silencing lentivirus of MIR99AHG and subjected to microCT analysis
Antisense overlapping long non-coding RNA regulates coding arachidonate 12-lipoxygenase gene by translational interference
Sabbir MG, et al.
Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1866(10), 158987-158987 (2021)
A fine-needle aspiration-based protein signature discriminates benign from malignant breast lesions
Franzen B, et al.
Molecular Oncology, 12(9), 1415-1428 (2018)
Nadia A Hasaneen et al.
American journal of physiology. Lung cellular and molecular physiology, 293(4), L1059-L1068 (2007-08-19)
Angiogenesis is an important feature of airway remodeling in both chronic asthma and chronic obstructive pulmonary disease (COPD). Airways in those conditions are exposed to excessive mechanical strain during periods of acute exacerbations. We recently reported that mechanical strain of
Comparison of in vitro viability methods for Cryptosporidium oocysts
Burgt NHV, et al.
Experimental Parasitology, 187, 30-36 (2018)
View All Related Papers

Articles

mRNA Synthesis for the Development of Vaccines and Therapeutics

Understand how mRNA vaccines induce immunity. and read how synthetic mRNA is prepared for vaccine immunogens and other biopharmaceuticals. Find reagents for synthesis of mRNA.

mRNA Synthesis for the Development of Vaccines and Therapeutics

Understand how mRNA vaccines induce immunity. and read how synthetic mRNA is prepared for vaccine immunogens and other biopharmaceuticals. Find reagents for synthesis of mRNA.

mRNA Synthesis for the Development of Vaccines and Therapeutics

Understand how mRNA vaccines induce immunity. and read how synthetic mRNA is prepared for vaccine immunogens and other biopharmaceuticals. Find reagents for synthesis of mRNA.

mRNA Synthesis for the Development of Vaccines and Therapeutics

Understand how mRNA vaccines induce immunity. and read how synthetic mRNA is prepared for vaccine immunogens and other biopharmaceuticals. Find reagents for synthesis of mRNA.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service